

EP GLOBAL COMMUNICATIONS, INC. / EPGL MEDICAL

Part A General Company Information

Item 1 The exact name of the issuer and its predecessor (if any).

EP GLOBAL COMMUNICATIONS, INC.

Item 2 The address of the issuer's principal executive offices.

EP Global Communications, Inc.
Scientific Research & Development
2192 Martin Street Suite 140
Irvine, CA 92612

Email Addresses:
information@epglmed.com
physicians@epglmed.com
investors@epglmed.com

Investor Relations & Public Relations Contact:
Mr. Brady Peterson
Email: investors@epglmed.com

Twitter:
@EPGLMed

Web:
www.EPGLMed.com

SECURITY INFORMATION

Ticker Symbol: EPGL
CUSIP# 268811205
ISIN# US2688112059

**Common Stock, Par Value .0001, 5 Billion Shares Authorized,
Outstanding Shares Approximately 4 Billion, 668 Million Shares
One Vote Per Share.**

As of September 30, 2016

5 Billion Authorized Common Shares
499,161,167 Float
4,500,838,833 Non-Float, Under
Restrictive Legend, Unissued or Retired
Total number of beneficial shareholders is 2
Total number of shareholders of record 700 approximate
Float and Non-Float numbers are approximate and may increase or decrease

The name and address of the transfer agent

Continental Stock Transfer & Trust Company
17 Battery Place 8th Floor
New York, NY 10004
212-509-4000
Registered Under the Exchange Act
Regulatory Authority: SEC, NYSE

ISSUANCE HISTORY

On July 27, 2012 a 10:1 Reverse Split was Affected as part of a major reorganization of the Company into a new medical device maker. The result of this action reduced outstanding shares issued from 4,991,611,670 (Billion) to 499,161,167 (Million) outstanding common shares. New common shares were issued to the following beneficial holders:

Pricewaterhouse Coopers, Corporate Finance and Recovery (Cayman)

Controlling Agent for:

AJW Qualified Partners, LLC, Ltd.

1.975 Billion Common Shares

Received Shares As Per Terms of Restructuring Agreement with Right to Additional 250mm Common Shares.

Mr. Michael Hayes

1.975 Billion Common Shares

Preferred Stock, Par Value .001, Class A, 5 Million Shares Authorized, 4.5 million Outstanding (190:1 Convertible to Voting Rights Equivalents of Common Shares)

Preferred Stock, Par Value 1.00 Class B, 5 Million Shares Authorized, 302

Outstanding (277:1 Convertible to Voting Rights Equivalents of Common Shares)

Received Shares As Per Terms of Restructuring Agreement with Right to Additional 250mm Common Shares.

DESCRIPTION OF BUSINESS PRODUCTS & SERVICES

Important Update :

EPGL has received two (2) USPTO patent allowances since our last updated disclosure. EPGL expects to report within the next quarterly update, a decision from the USPTO on one or more additional patents pending. EPGL will inform our shareholders via public release immediately upon receiving such notice from the USPTO .

On April 12, 2016 EPGL signed an Agreement with Johnson & Johnson Vision Care, Inc. (JNJVC) . EPGL has several patents now pending in the field of ophthalmic technologies, specifically the integration of electronics into contact lenses for vision correction and augmented vision applications. JNJVC has secured exclusive rights of first negotiation to all EPGL ophthalmic technologies and patents pending. EPGL has received two (2) USPTO patent allowances since our last updated disclosure.

EPGL and CooperVision, Inc. reached a Settlement Agreement in December 2015. In December 2014, CooperVision, Inc. asked EPGL to grant the Exclusive Option to license EPGL jointly developed ophthalmic technologies. EPGL refused to do so, contending that the Development Agreement was breached and did not allow the granting of the Option for several more months after all joint IP was fully filed. EPGL threatened litigation over the issue. In May 2015, CooperVision, Inc. suggested mediation and EPGL agreed to do so. As announced publicly in a jointly approved January 2016 PR, after several months of negotiations, a settlement was reached whereby, to avoid litigation, the parties would agree that CooperVision, Inc. will retain rights and license to use the joint technology in their products in exchange for cash payment and EPGL receiving assignment of the IP and 100% ownership control and marketing rights worldwide.

EP Global Communications, Inc., is a research and development company with focus on medical device design, ophthalmic medical device design, consumer electronic device design and device technologies in the IoT space.

In 2014, all EPGL technologies and Intellectual property were selected and put under Development Agreement by CooperVision, Inc., a leading medical device manufacturer, for development and marketing. The EPGL team is now securing Intellectual Properties and co-developing a family of advanced devices as a result. This Development Agreement was publicly disclosed on August 29, 2014. In addition, EPGL has entered an initial Agreement with Intel Corporation. EPGL has also entered into Agreements with AT&T as of January 2015. EPGL and AT&T have created joint Intellectual Properties and are now in the process of procuring those properties.

EPGL Medical is the result of a reorganization which culminated in July 2012. With a strong team of medical and scientific professionals, the Company is poised to capture market share with innovative “smart medical and consumer electronic devices” technologies including those that require advanced microelectronic mechanical systems (MEMS). The Company philosophy is that healthcare is going to become an increasingly challenging environment for both physicians and patients. A coming boom in patients simultaneous to a possible shortage of physicians will necessitate intuitive medical devices which can be used by a broader variety of doctors. In short, new “smart medical devices” advanced research and design intellectual properties will be needed more than ever. EPGL Medical has the know-how to develop technologies which fit this coming new healthcare environment and enable industry leaders to capture market share with those advanced technologies.

EP Global Communications, Inc. dba EPGL Medical, is a Delaware Corporation first incorporated November 17, 1999.

SIC Code 3841 - Surgical and medical instruments, Development Stage Company

FISCAL YEAR END DATE IS: JUNE 30

The Company has significant know-how and Intellectual Property in the arena of BioMEMS. The Company has invented new device technologies which include, but are not limited to the following:

**Advanced Technologies for Contact Lenses
Advanced Cell Regeneration Technology to Treat Eye Disease
Advanced Cell Regeneration Technology to Treat Hearing Loss
Advanced Nerve Ablation Device
Advanced Epidural Device
Advanced Trigger Point Needle Device**

Advanced Micron Resolution Motor for Smart Medical Devices
Advanced Platform Technology for Development of Smart Medical devices
Real-Time Sensor Technologies for Connectivity to a Global Network
Real-Time Data Applications for Athletic Teams, Workforces and Military Forces.

The company has brought on-board a Team of Medical and Engineering professionals which are highly accomplished in their respective fields:

David T. Markus Ph.D.

Company Vice President - BioMems Development

David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery. Finally, Dr. Markus is fluent in English, Chinese-Madarin, Taiwanese-FuJian and Indonesian languages. A full bio for Dr. Markus will be made available on the Company website in the near future.

Company Medical Director - Corey W. Hunter M.D.

Corey W. Hunter, MD is based in New York City. He completed his residency in physical medicine and rehabilitation at NYU Langone Medical Center and a fellowship in pain medicine at Weill Cornell Medical College. Dr. Hunter's specialties include pain diagnosis and treatment, disorders of the spine and peripheral nervous system, with a special interest in advanced interventional techniques and minimally invasive spinal procedures. Dr. Hunter was pivotal in conducting early research on the MPDD device. Along with NYU physicians, Michel Dubois M.D. and Shengping Zou M.D., Dr. Hunter headed the team which published one of the first research studies showing significant improvement for the detection of pain caused by muscles, using the MPDD device versus traditional manual pressure (MP) for the diagnosis and treatment Myofascial Pain Syndrome which can include chronic back pain, neck pain, migraine, fibromyalgia and more. These findings greatly contributed to the early progress of the MPDD development and its subsequent FDA 510k clearance and patent awards.

Eric Lee M.D.M.A.

Eric Lee M.D. M.A. graduated from Yale University and completed medical school at Boston University. He completed his residency in Physical Medicine and Rehabilitation at NYU Langone Medical Center where he has continued with a Pain Medicine fellowship. Dr. Lee is intimately familiar with the MPDD device and used it as a diagnostic tool in a study of using advanced techniques to treat myofascial pain along with Dr. Michel Dubois MD at NYU. Dr. Lee's professional interests include pain diagnosis and treatment, disorders of the spine, central,

and peripheral nervous system, with a special interest in advanced interventional techniques and minimally invasive spinal procedures. Dr. Lee will oversee further additions to the EPGL Medical management team and advancement of new medical devices technologies the Company has interest in pursuing.

Ryan M. Stellar M.E. B.E.

EPGL is proud to have Ryan M. Stellar M.E. B.E. as part of the team. Mr. Stellar is a highly accomplished biomedical engineer who was intimately involved with the creation of the MPDD device as the Chief Engineer during its creation at Stevens Proof of Concept (SPOC). Mr. Stellar graduated from Stevens Institute of Technology in 2006 with a degree in Biomedical Engineering and a Minor in Economics. Mr. Stellar has been with Medtronic, Inc. for six years prior to leaving this year. While at Medtronic, among many other accomplishments, he successfully directed global launches of two portfolio critical products in the cardiac rhythm device market: DF4 Lead Connector System & CareLink Network for Heart Failure. Mr. Stellar is an expert in medical device manufacturing resources and distribution channels as well as customer relationship management.

Vice President of Emergency Medicine Innovations

Noah T. Kaufman, M.D.

Noah T. Kaufman, M.D. as Vice President of Emergency Medicine Innovations and candidate for Board of Directors. Dr. Kaufman will add valuable energy and insight from the perspective of emergency medicine, which is a significant market for EPGL moving into the future. He is a highly accomplished physician in his field. As Director of Clinical Emergency Ultrasound, Dr. Kaufman is in the top ranks for patient scores and outcomes. Dr. Kaufman is also currently the attending Emergency Physician for Barton Memorial Hospital ER and the Carson Valley Medical Center ER at South Lake Tahoe, California. His education includes Akron General Medical Center, Akron, OH - EM Residency 2006. Tulane University School of Medicine, New Orleans, LA - MD 2003, and University of Miami, Coral Gables, FL - BS 1996

Company President & CEO - Michael Hayes

Michael Hayes was President of Digital Health Sciences, Inc. prior to that Company being acquired by EPGL in July 2012. Mr. Hayes has presided over the debt restructuring of EP Global Communications, Inc. along with Pricewaterhouse Coopers since early 2012. Mr. Hayes is now in charge of assembling a new management team for EPGL, including all Company management, medical and scientific personnel going forward. Mr. Hayes has made it a singular priority to bring aboard only the world's top professionals in the field of medical sciences to EPGL and thereby build the Company into a major player in the medical device industry over the next several years. Mr. Hayes has also committed to prioritizing shareholders and creating significant value for their investments over time.

IR/PR Manager Mr. Brady Peterson

Brady Peterson was recently named Manager of Investor Relations and Public Relations as well as Information Technologies for EPGL Med. Mr. Peterson is the consummate professional who brings 15 years of Customer Relations and marketing experience to EPGL. The EPGL team is pleased to have him aboard and we believe customers and investors alike will appreciate his professionalism.

ISSUERS FACILITIES

The Company leases or utilizes facilities in the following locations:
Various California Bay Area Research Facilities Under NDA, Florida Facilities,
David T. Markus, Ph.D. Irvine, California – Research Facilities, Office
NYU Langone Medical Center, Corey W. Hunter M.D. / Eric Lee M.D.
University of Minnesota, David T. Markus, Ph.D.
University of California at Irvine, David T. Markus, Ph.D.
Dallas and Plano Texas, David T. Markus, Ph.D.

OFFICERS, DIRECTORS and CONTROL PERSONS

The name of the chief executive officer, members of the board of directors, as well as control persons.

President, CEO and Director, Michael Hayes
Private Investor, Corporate Restructure Specialist.
Will hold Board Membership and will assign 3 other Board Members

Pricewaterhouse Coopers will appoint 3 additional Board Members on behalf of AJW Qualified Partners.

Company is compensating both parties via 2.25 billion shares each, as disclosed previously.

Disciplinary History of Officers, Directors and Control Persons

None

Beneficial Shareholders

**AJW Qualified Partners, LLC,
1.975 Billion Common Shares
Controlling Agent is Pricewaterhouse Coopers , Corporate Finance
and Recovery (Cayman) Ltd.
5th Floor Strathvale House, P.O. Box 258 Grand Cayman, Cayman
Islands, KY1 1104**

Michael Hayes

1.975 Billion Common Shares

**Preferred Stock, Par Value .001, Class A, 5 Million Shares Authorized, 4.5 million
Outstanding (190:1 Convertible to Voting Rights Equivalents of Common Shares)**

**Preferred Stock, Par Value 1.00 Class B, 5 Million Shares Authorized, 302
Outstanding (277:1 Convertible to Voting Rights Equivalents of Common Shares)**

1582 Deere Avenue

Irvine, CA 92606

THIRD PARTY PROVIDERS

Matthew Ladin, Esq.

829 De La Vina Street, Suite 200

Santa Barbara, California 93101

805-698-3075

ITEM 10 ISSUER CERTIFICATION

I, Michael Hayes, certify that:

- 1. I have reviewed this initial quarterly disclosure statement of EP Global Communications, Inc.;**
- 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and**
- 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.**

9-30-2016

/s/ Michael Hayes

Michael Hayes

President and CEO

Safe Harbor Statement

Certain matters discussed in this report are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.